United States

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

2 Dec 2016
Change (% chg)

$0.01 (+0.84%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for INFI.OQ


Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)


Beta: 2.21
Market Cap(Mil.): $57.19
Shares Outstanding(Mil.): 49.73
Dividend: --
Yield (%): --


  INFI.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.94 -- --
ROI: -24.09 -1.09 14.95
ROE: -39.33 -2.39 16.29

BRIEF-Bristol-Myers, Infinity Pharma to evaluate Opdivo with IPI-549 in advanced solid tumors

* Bristol-Myers Squibb and infinity pharmaceuticals announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with IPI-549 in advanced solid tumors

Nov 09 2016

BRIEF-Verastem licenses duvelisib from infinity pharmaceuticals

* Verastem is obligated to pay to infinity up to $28 million in milestones

Nov 02 2016

BRIEF-Verastem licenses Duvelisib from Infinity Pharmaceuticals

* Verastem inc says under terms of license agreement, Verastem is obligated to pay to Infinity up to $28 million in milestones Source text for Eikon: Further company coverage:

Nov 02 2016

BRIEF-Infinity Pharma Q2 earnings per share $1.05

* Infinity provides company update and reports second quarter 2016 financial results

Aug 09 2016

BRIEF-Infinity Pharmaceuticals sees workforce restructuring completed by year-end

* Expects to incur severance, benefits and related costs of about $8 million

Jun 28 2016

BRIEF-Infinity regains worldwide rights to duvelisib; ends collaboration with AbbVie

* Says neither infinity nor abbvie have future financial obligations to other party

Jun 28 2016

BRIEF-Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln

* Expects restructuring to be substantially completed by july 1, 2016 and to be fully completed by december 31, 2016

Jun 14 2016

BRIEF-Infinity Pharmaceuticals Inc reports topline results from DYNAMO(tm)

* Majority of reported side effects were reversible and clinically manageable.

Jun 14 2016

Earnings vs. Estimates